Haaris Naji, DO
Pulmonary Disease · Montclair, CANPI 1023582194
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (48.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 69.1% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $13,392 and has fallen 63.7% since, to $4,859 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $69.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$15K
- GSK$2K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$427
- Sanofi$394
- Merck$335
- plus $3K from 30 others
What the payments were for
- Speaking & faculty fees$2,0009%
- Travel & lodging$2,19910%
- Food & beverage$7,02632%
- Education$10,67949%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 18 | $15,141 |
| GSK | 106 | $1,886 |
| AstraZeneca(2 entities) | 48 | $1,188 |
| Regeneron Healthcare Solutions, Inc. | 16 | $427 |
| Sanofi | 17 | $394 |
| Merck | 14 | $335 |
| Boehringer Ingelheim | 12 | $296 |
| Amgen | 16 | $286 |
| Genentech USA, Inc. | 7 | $232 |
| Grifols USA, LLC | 8 | $200 |
| Bayer | 3 | $157 |
| United Therapeutics Corporation | 6 | $157 |
| UCB, Inc. | 1 | $124 |
| Penumbra, Inc. | 1 | $109 |
| Insmed, Inc. | 3 | $91 |
| Actelion Pharmaceuticals US, Inc. | 4 | $88 |
| ANI Pharmaceuticals, Inc. | 3 | $82 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Verona Pharma, Inc. | 3 | $65 |
| Cook Medical LLC | 2 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Philips North America LLC | 3 | $52 |
| Johnson & Johnson | 3 | $49 |
| Mallinckrodt Hospital Products Inc. | 2 | $45 |
| Baxter Healthcare | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 2 | $36 |
| Shionogi Inc | 1 | $35 |
| Mylan Specialty L.p. | 2 | $33 |
| Lilly USA, LLC | 1 | $28 |
| La Jolla Pharmaceutical Company | 1 | $24 |
| Electromed, Inc. | 1 | $23 |
| Nabriva Therapeutics, PLC | 1 | $22 |
| Novartis | 1 | $22 |
| Viatris Specialty LLC | 1 | $21 |
| Dexcom, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,919
- ION$3,000
- DA VINCI SP$2,000
- TEZSPIRE$244
- Adempas$125
- Nayzilam$124
- Indigo System$109
How this compares
$21,904 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 26 | $302,400 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 195 | $160,306 |
| Spiriva RespimatTiotropium Bromide | 46 | $30,438 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $29,250 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $16,159 |
| EliquisApixaban | 14 | $8,720 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $7,044 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 181 | $6,866 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $6,746 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,097 |
| BreynaBudesonide/Formoterol Fumarate | 25 | $3,922 |
| Wixela InhubFluticasone Propion/Salmeterol | 37 | $3,691 |
| Varenicline Tartrate | 15 | $3,126 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,729 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $296 | $339,88286 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,886 | $166,403211 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,188 | $35,99758 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Montclair
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.